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Background: Colorectal cancer has become one of the leading cause of cancer morbidity and mortality
throughout world. Hederagenin, a derivative of oleanolic acid isolated from the leaves of ivy (Hedera helix L.), has
been shown to have potential anti-tumor activity. The study was conducted to evaluate whether hederagenin could
induce apoptosis of human colon cancer LoVo cells and explore the possible mechanism.
Methods: MTT assay was used for evaluating cell viability while Annexin V-FITC/PI assay and Hoechst 33342 nuclear
stainining were used for the determination of apoptosis and mitochondrial membrane potential. DCFH-DA
fluorescence staining and flow cytometry were used to measure ROS generation. Real-time PCR and western blot
analysis were performed for apoptosis-related protein expressions.
Results: MTT assay showed that hederagenin could significantly inhibit the viability of LoVo cells in a
concentration-dependent and time-dependent manner by IC50 of 1.39 μM at 24 h and 1.17 μM at 48 h. The
apoptosis ratio was significantly increased to 32.46% and 81.78% by the induction of hederagenin (1 and 2 μM) in
Annexin V-FITC/PI assay. Hederagenin could also induce the nuclear changes characteristic of apoptosis by Hoechst
33342 nuclear stainining under fluorescence microscopy. DCFH-DA fluorescence staining and flow cytometry
showed that hederagenin could increase significantly ROS generation in LoVo cells. Real-time PCR showed that
hederagenin induced the up-regulation of Bax and down-regulation of Bcl-2, Bcl-xL and Survivin. Western blotting
analysis showed that hederagenin decreased the expressions of apoptosis-associated proteins Bcl-2, procaspase-9,
procaspase-3, and polyADP- ribosepolymerase (PARP) were increased, while the expressions of Bax, caspase-3,
caspase-9 were increased. However, there was no significant change on caspase-8.
Conclusions: These results indicated that the disruption of mitochondrial membrane potential might contribute to
the apoptosis of hederagenin in LoVo cells. Our findings suggested that hederagenin might be a promising
therapeutic candidate for human colon cancer.
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Mounting evidence showed that colorectal cancer is the
most frequently diagnosed cancer and the second leading
cause of cancer-related death [1,2]. Several epidemio-
logical studies have reported that the mean cumulative in-
cidence rate of colorectal cancer is 3.1% at 10 years [3,4].
The risk of this disease is multifactorial, such as age, envir-
onmental, genetic, and dietary factors. The etiology of
colorectal cancer is also limited, Currently, therapeutic
methods for human colorectal cancer include radiother-
apy, chemotherapy and surgery [5]. However, these strat-
egies for the treatment of colorectal cancer are not
satisfactory. Therefore, effective strategy needs to be devel-
oped to decrease the morbidity and mortality of colorectal
cancer.
Apoptosis plays an important role in the transition
from normality to malignancy on colorectal cancer and
the regulation of tissue development and homeostasis
[6]. Apoptotic cell can be executed by the extrinsic and
the intrinsic activated signaling pathways in the intes-
tinal tract [7]. There was a growing body of evidence
from mutiple studies showed the fact that the apoptosis
was related closely to the loss of mitochondrial mem-
brane integrity [8,9]. The over-generation of reactive
oxygen species (ROS) may contribute to the apoptosis
through regulating Bcl family proteins, releasing cyto-
chrome c from the mitochondria, and activating caspases
such as caspase-3 and caspase-9 [9]. It is a promising
emerging strategy for the prevention and treatment of
colorectal cancer via inducing apoptosis which was medi-
ated by mitochondria.
Hederagenin, a derivative of oleanolic acid isolated
from the leaves of ivy (Hedera helix L.), has a strong
anti-tumor effect both in vitro and in vivo [10]. Its sap-
onin macranthoside B has been shown to induce apop-
tosis in various kinds of cancer cells through activating
the caspase cascades for intrinsic pathways and regulat-
ing the protein level of Bcl-2 and Bax, as well as Bax/
Bcl-2 ratio [11]. In addition, the bidesmosides of hedera-
genin are able to induce apoptosis in HeLa cells [12].
However, there is a limited report on the induction of
hederagenin on apoptosis in colorectal cancer cells. In
this study, we examined whether hederagenin could in-
duce apoptosis in LoVo cells to inhibit the proliferation
of tumor cells. Furthermore, the mechanism of hedera-
genin on inducing apoptosis of LoVo colon cells was
also explored, including the mitochondrial pathway and
the expressions of apoptosis-related proteins.
Methods
Reagent
Hederagenin ((3 beta, 4alpha)-3,23-dihydroxyolean-12-
en-28-oic acid, C30H48O4, molecular weight = 472.70,
purity ≥ 97%) was isolated in our laboratory from theleaves of ivy (Hedera helix L.) which was collected from
Shaoyang City, Hunan Province of China at October 22,
2012. The voucher specimen of the leaves has been depos-
ited at the Plant Resources Herbarium, Jiangsu Provincial
Academy of Chinese Medicine (No. ZYY-2012103004).
The chemical structure of hederagenin was shown in
Figure 1. Dulbecco’s modified Eagle’s medium (DMEM)
and bovine serum were from Life Technologies (Grand
Island, NY). TRIzol reagents were obtained from Invitro-
gen (Carlsbad, CA). JC-1 detection kit was purchased from
KeyGEN Biotechnology (Nanjing, China). Primescript RT
reagent kit with gDNA Eraser and SYBR Premix Ex Taq
were from TaKaRa (Dalian, China). Antibodies against
caspase-3, caspase-9, caspase-8 were from Cell Signaling
Technology (Beverly, MA). Antibodies against Bcl-2 or
Bax were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Annexin V-fluorescein isothiocyanate (FITC)
and propidium iodide (PI) apoptosis detection kit was
from BD Biosciences (San Diego, CA). The horseradish
peroxidase (HRP) labeled goat anti-mouse IgG or anti-
rabbit antibody were from Beijing Zhongshan Biotech
Company (Beijing, China). Other reagents are analytical
grade from commercial sources.Hederagenin preparation
One hundred g leaves of ivy (Hedera helix L.) were
immersed in 90% ethanol (v/v) for two hours, then
refluxing was used to extract three times with the
3000 mL ethanol every two hours. Extraction liquid of
three times was merged and filtered. The filtrate was ro-
tary evaporated to recycle the ethanol to obtain the
crude extract and then was added to 30 times acid hy-
drolyzate solution, which was consisted of 95% ethanol
and hydrochloric acid. The liquid volume fraction of
hydrochloric in mixed liquid was 7%, while ethanol was
50%. The process of three-hour acid hydrolysis was set
at the temperature of 80°C. After acid hydrolysis, the
mixed liquid was recovered ethanol to without alcohol
taste. The liquid was allowed to cool and deposit at
room temperature. Precipitate, was washed with a little
distilled water and dried under reduced pressure at 65°C
to prepare hederagenin. The chemical structure of this
compound has been identified.Cell culture
Human LoVo colon cancer cell line was obtained from
Type Culture Collection, Chinese Academy of Sciences
(Shanghai, China) and incubated in DMEM supple-
mented with 10% fetal bovine serum (FBS), penicillin
(100 U/ml) and streptomycin (100 μg/ml) at 37°C in a
water-saturated atmosphere with 5% CO2. These cells
were cultured in 25 cm2 cell culture flasks. Medium was
replaced every 2 days. Cells treated with equal amount
Figure 1 The chemical structure of hederagenin (C30H48O4, molecular weight = 472.70).
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as a negative control.
MTT assay
MTT assay was performed to determine cell viability ac-
cording to the previous method [13]. Briefly, LoVo cells
were seeded into 96-well plates at a density of 10,000
cells/well. After being treated with 0.25, 0.5, 1.0, 2.0 and
4.0 μM hederagenin for 24 or 48 h according to our pre-
test results, the medium was discarded and treated with
20 μl MTT (5 mg/ml). After incubation for 4 h at 37°C,
the 100 μl DMSO was added to each well to dissolve the
resultant formazan crystals. Absorbance was detected at
490 nm by using ELx800 microplate reader (BioTek,
Winooski, VT) [14].
Hoechst 33342 nuclear staining
Apoptotic morphological alterations in the nuclear chro-
matin were detected by Hoechst 33342 staining. The
cells at a density of 3 × 105 per well were grown onto
cover slips in 6-well plates. After incubation for 24 h,
these cells were treated with 1 and 2 μM hederagenin
for 48 h. These cells were washed with phosphate buffer
saline (PBS) and stained with Hoechst 33342 for 30 min
in CO2 incubator [15]. After rinsed three times in PBS,
the cells were examined for nuclear changes (i.e., chro-
matin condensation and nuclear fragmentation) charac-
teristic of apoptosis under fluorescence microscopy.
Apoptosis assay
Induction of apoptosis was assessed by the binding of
annexin V-FITC/PI to phosphotidylserine. Briefly, thesecells (1 × 106) were treated with 1 and 2 μM hederagenin
for 48 h. Cells were harvested and suspended in binding
buffer. An aliquot of 300 μl was incubated with 3 μl of
Annexin V-FITC and 3 μl of propidium iodide (PI) for
20 min at room temperature in the dark. The stained
cells were analyzed by fluorescent activated cell sorting
(FACS) on a FACScan flow cytometer (Becton Dickinson)
at an excitation wavelength of 488 nm and observation
wavelengths of 530 and 575 nm [16,17].
Measurement of mitochondrial membrane potential
Mitochondrial membrane potential was assessed by mea-
surement with 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-
benzamidazolylcarbocyanine iodide (JC-1;Molecular Probes;
T3168). Cells (1 × 106) were treated with 1 and 2 μM
hederagenin, harvested and washed twice with cold PBS.
The cells were incubated for 30 min at 37°C with the
fresh culture medium containing JC-1 of 2.5 μg/ml. Cells
were collected by centrifugation at 2000 g for 5 min and
incubated with 10 μg/ml JC-1 dye for 30 min, and then
washed once with DMEM. Both red and green fluores-
cence emissions were analyzed by flow cytometry using
an excitation wavelength of 488 nm and emission wave-
lengths of 530 nm (green fluorescence)/585 nm (red
fluorescence). An increase in green fluorescent (FI) inten-
sity represents mitochondrial swelling, whereas a decrease
in red fluorescence indicates loss of mitochondrial mem-
brane potential [18].
Flow cytomertry detection of reactive oxygen species (ROS)
The levels of ROS in LoVo cells were stained by 2,7-
dichlorodihydrofluorescein diacetate (DCFH-DA, Sigma)
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cells/ml) were treated with 1 and 2 μM hederagenin for
48 h to detect the changes of ROS. These cells were har-
vested and washed twice with PBS, and then re-suspended
in 500 μl of DCFH-DA solution (10 μM). After being in-
cubated at 37°C for 30 min, the levels of ROS were ana-
lyzed by flow cytometry at an excitation 488 nm and
emission 525 nm.
Quantitative real-time PCR
Total RNA was isolated by using the TRIzol reagent
(Invitrogen, Carlsbad, CA) following the manufacturer’s
instructions. Briefly, after being treated with hederagenin
for 48 h, these cells were resuspended in 1 ml of TRIzol.
The suspension was extracted with 0.2 ml of chloroform.
After being centrifuged with 2000 g for 5 min and mixed
with 0.5 ml of isopropyl alcohol, the resultant pellet was
washed with 0.7 ml of 75% ethanol and finally resus-
pended in 50 μl RNase-free water. All total RNA sam-
ples were kept at −80°C. The primers for human cDNA
synthesis were performed using iScript select cDNA syn-
thesis kit (Bio-Rad). Each sample was tested in triplicate,
with the use of the Quantitect SYBR Green PCR kit
(Qiagen, Hilden, Germany) for 40 cycles (95°C for 10 min,
95°C for 15 s, and 60°C for 1 min) on the ABI 7900HT fast
real time PCR System (Applied Biosystems, Foster, CA).
The primers were as follows: β-actin forward primer,
GGCCAACCGCGAGAAGAT, β-actin reverse primer,
CGTCACCGGAGTCCATCA; Bax forward primer, TTT
GCTTCAGGGTTTCATCC, Bax reverse primer, GCCAC
TCGGAAAAAGACCTC; Bcl-2 forward primer, ATGAA
CTCTTCCGGGATGG, Bcl-2 reverse primer, TGGATCC
AAGGCTCTAGGTG; Bcl-xL forward primer, TCGCCCT
GTGGATGACTGAG, Bcl-xL reverse primer, CAGAGT
CTTCAGAGACAGCCAGGA; Survivin forward primer,
TTCTCAAGGACCACCGCATC; Survivin reverse primer,
GCCAAGTCTGGCTCGTTCTC. Cycle threshold (Ct)
values were obtained graphically for the target genes and
β-actin. The difference in Ct values between GAPDH and
target genes were represented as ΔCt values. ΔΔCt values
were obtained by subtracting ΔCt values of control samples
from those of treated samples. The relative fold change in
gene expression was calculated as 2-ΔΔCt [19,20].
Protein extraction and western blotting analysis
These cells were treated with 1 and 2 μM hederagenin
in 100 mm-diameter culture dishes for 48 h. After treat-
ment, the cells were washed twice with ice-cold PBS,
and harvested by scraping in 200 μl of lysis buffer
[20 mM Tris–HCl (pH = 8.0), 1 mM sodium orthovana-
date, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride,
2 mM EDTA, 1% Triton X-100, 50 mM β-glycerolpho-
sphate and 10 mg/ml each of aprotinin, leupeptin and
pepstatin]. Eighty micrograms of proteins which wasdetermined by BCA protein assay kit was separated elec-
trophoretically using a 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel and
transferred to a polyvinylidene fluoride (PVDF) mem-
brane. The membrane was incubated at 4°C overnight in
5% skim milk in TBST (20 mM Tris–HCl, pH 7.6,
150 mM NaCl, and 0.05% Tween-20) containing primary
antibodies at one of the following: Bax (1:1000), Bcl-2
(1:1000), caspase-3 (1:500), caspase-9 (1:500), PARP
(1:500) or β-actin (1:1000). After washing with TBST
for three times, the membrane was incubated with
goat anti-rabbit IgG HRP conjugated secondary anti-
body (1:1000) or goat anti-mouse IgG HRP conjugated
secondary antibody (1:1000) for 1 h at room temperature
[21,22]. Immunodetection was performed with an en-
hanced chemiluminescence (ECL) detection kit (Cell Sig-
naling Technology, Beverly, MA). The protein brands
were analyzed using densitometry scanning with the
Chemilmager™ 5500 fluorescence system equipped with
the analysis software AlphaEase FC™ (Alpha Innotech Cor-
poration, San Leandro, CA 94577, USA).
Measurement of lactate dehydrogenase
To measure lactate dehydrogenase (LDH) release, 100 μl/
well supernatant medium collected from above Hoechst
33342 staining experiment was transferred to the corre-
sponding well of an optically clear 96-well flat-bottom mi-
crotiter plate and analyzed using an LDH cytotoxicity
detection kit (KeyGEN, Nanjing, China), according to the
manufacturer’s instructions. LDH activity was calculated
by measuring the increase in absorbance at 450 nm.
Statistical analysis
All data are from at least three individual experiments
and are expressed as mean ± standard deviation (SD).
Statistical comparisons of the results were evaluated
using analysis of variance (ANOVA) with SPSS 13.0. Sig-
nificant differences between the control and treated cells
were analyzed by Student’s t-test (*p < 0.05 or **p < 0.01)
Results
Effects of hederagenin on LoVo cell viability
The effect of hederagenin on LoVo cell viability was exam-
ined by MTT assay (Figure 2). LoVo cells were treated
with hederagenin (0.25, 0.5, 1.0, 2.0 and 4.0 μM) for 24
and 48 h, respectively. The exposure of LoVo cells to
hederagenin resulted in a significant decrease of cell via-
bility. After treatment with hederagenin (1.0, 2.0 and
4.0 μM), the inhibitive rates were 40.50 ± 4.33%, 78.78 ±
5.21% and 83.44 ± 3.77% for 24 h while 47.16 ± 6.37%,
90.78 ± 5.39% and 91.35 ± 5.22% for 48 h. The IC50 for
hederagenin in LoVo cells were 1.39 μM at 24 h for and
1.17 μM at 48 h, respectively. These results suggested that
Figure 2 The effect of hederagenin on cell proliferation of LoVo cells. The cells were incubated with the indicated concentrations of
hederagenin for 24 and 48 h. DMSO of 0.04% was used as the control. The data are expressed as means ± standard deviation from three
independent experiments (n = 12).
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inhibitive effect on the proliferation of LoVo cells.
Effects of hederagenin-induced LoVo cell apoptosis
To further confirm the apoptosis of hederagenin, LoVo
cells were stained with Annexin V/PI, and subsequently
analyzed by flow cytometry. As indicated in Figure 3A,
after being treated for 48 h, the percentage of apoptotic
cells was increased by hederagenin. The total apoptotic
rates of hederagenin (1 and 2 μM) were 32.46% and
81.78%, respectively, whereas the apoptotic rate was only
at 1.57% for the control. To investigate the morpho-
logical alterations after hederagenin treatment, cells wereFigure 3 Hederagenin-induced apoptosis (A) and apoptotic morpholo
2 μΜ hederagenin. LL(lower left), living cells (AV/PI negative); LR (lower righ
apoptotic cells (AV positive/PI positive); UL(upper left), necrotic cells(AV neg
in the sum of upper right and lower right quadrants. For apoptotic morph
staining and measured by fluorescence microscopy (magnification 200×).monitored using Hoechst 33342 staining. Herein, the
characteristic features of apoptosis including chromatin
condensation and nuclear fragmentation in hederagenin-
treated cells were observed as compared with the con-
trol cells (Figure 3B). These results demonstrated that
the inhibition of hederagenin on the growth of LoVo
cells was associated with its induction of apoptosis.
Effects of hederagenin on mitochondrial membrane
potential disruption and ROS level
ROS has been found to play an important role in indu-
cing apoptosis of tumor cells. To observe the level of
ROS, the LoVo cells were stained with DCFH-DA, andgical changes (B) in LoVo cells. a, control; b, 1 μΜ hederagenin; c,
t), early apoptotic cells (AV positive/PI negative); UR (upper right), late
ative/PI positive). The numbers represent the percentage of the cells
ological changes, apoptotic cells were detected by Hoechst 33342
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with 1 and 2 μM hederagenin, the ROS level in LoVo
cells was increased as compared with blank control
(*P < 0.05, **P < 0.01). the treatment of hederagenin led
to an increase of ROS levels in the examined LoVo
cells (Figure 4A and B).
An involvement of mitochondria in the mechanisms of
hederagenin-induced apoptosis was determined accord-
ing to a ratio of red fluorescence of JC-1 aggregates and
green fluorescence of JC-1 monomers. The aggregation
of monomers is directly correlated to mitochondrial
membrane potential, and their breakdown in dying cells
results in a increase of green fluorescence. As shown in
Figure 4C and D, JC-1 aggregates accumulated in con-
trol cells and displayed high ratio of red fluorescence.
Hederagenin (1 and 2 μM)-treated cells resulted in a
higher green fluorescence with a decrease of red fluores-
cence intensity. The decrease of red/green fluorescence
ratio showed that the disruption of MMP were 53.81 ±
5.15% and 31.41 ± 4.23%, respectively (*P < 0.05, **P <
0.01). Data showed that hederagenin could down-regulate
MMP, indicating the important role of mitochondria in
hederagenin-induced apoptosis.
Effects of hederagenin on mRNA expression levels of Bax,
Bcl-2, Bcl-xL and Survivin
Bcl-2 family was served as vital regulators of the mito-
chondrial pathway involved in apoptosis. To investigate
whether hederagenin could regulate the Bcl-2 family
including Bax, Bcl-2, Bcl-xL, and Survivin mRNA, RT-
PCR was used to quantity the levels of these mRNA.
Figure 5 showed that hederagenin at the concentration
of 1 and 2 μM could increase Bax mRNA level while de-
crease Bcl-2, Bcl-xL and Survivin mRNA level in LoVo
cells. These results indicated that the induction of heder-
agenin on apoptosis might be associated with Bax, Bcl-2,
Bcl-xL and Survivin.Figure 4 The level of ROS after treatment were measured using DCFH
b, 1 μΜ hederagenin; c, 2 μΜ hederagenin. The mitochondrial membrane
flow cytometry. The reduced MMP indicated by a decrease in red fluoresce
Each experiment was conducted in triplicate. *P < 0.05, **P < 0.01, vs. contrEffects of hederagenin on the expression of Bax, Bcl-2
and caspases
To explore the regulation of hederagenin on apoptotic
proteins, western blot analysis was conducted to evaluate
the expressions of Bcl-2, Bax, procaspase-9, procaspase-
3 and proPARP proteins. After treatment with hedera-
genin for 48 h, a significant decrease of Bcl-2 (26 kDa),
procaspase-9 (47 kDa), procaspase-3 (35 kDa), proPARP
(116 kDa) in LoVo cells was observed in 1 or 2 μM
hederagenin-treated LoVo cells groups compared with
control group (P < 0.01). However, the protein expres-
sion of Bax was (23 kDa) significantly increased by
hederagenin (1 or 2 μM) (Figure 6A and B). The results
of western blotting analysis demonstrated that the indu-
cing apoptosis of hederagenin in LoVo cells through
modulating Bcl and caspase families pathway, which was
associated with mitochondrial membrane potential dis-
ruption. In order to confirm this pathway, caspase-9,
caspase-3 and caspase-8 activation were observed in
LoVo colon cancer cells. As shown in Figure 7A and B,
hesderagenin increased caspase-9 and caspase-3 activa-
tion. However, there were no significant changes on
caspase-8 activation. The resutls indicated that the in-
duction of hederagenin on apoptosis of LoVo colon can-
cer cells might be achieved via intrinsic pathway rather
than extrinsic pathway.
LDH activity of hederagenin on LoVo cell
LDH activity in the medium treated with hederagenin was
significantly increased (*P < 0.05, **P < 0.01) (Figure 8).
The result showed that the activities of LDH when treated
with hederagenin (1 or 2 μM) were 68.25 ± 4.63 and 82.96 ±
9.11 U/L, respectively.
Discussion
It has also been shown that hederagenin isolated from the
leaves of ivy (Hedera helix L.) is effective in decreasing cell-DA (A, B) or JC-1 stainings (C, D) by flow cytometry. a, control;
potential (MMP) after treatment were measured using JC-1 staining by
nce. The green gluorescence represents the monomeric form of JC-1.
ol.
Figure 5 Effects of hederagenin on mRNA levels of Bcl-2, Bcl-xL, Bax and Survivin. The mRNA expressions were measured by quantitative
RT-PCR and calculated as % of DMOS-only control. β-actin was used as an internal control. *P < 0.05, vs. control (n = 3).
Figure 6 The effects of hederagenin on the expressions of apoptosis-related proteins (A) and their protein levels (B), such as Bax, Bcl-2,
procaspase-9, procaspase-3 and proPARP in LoVo cells. Expressions of Bcl-2, procaspase-9, procaspase-3, proPARP were significantly reduced
when the LoVo cells were treated with 1 and 2 μΜ hederagenin for 48 h, while the reverse was true for the expression of Bax. The data are
expressed as means ± standard deviation from three independent experiments (n = 3).
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Figure 7 The effects of hederagenin on the expressions of caspase-9, caspase-3 and caspase-8 (A) and their protein levels (B) in LoVo
cells. The data are expressed as means ± standard deviation from three independent experiments (n = 3).
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through inbibiting proliferation and inducing apoptosis.
Briefly, apoptosis is mediated by two central pathways: the
extrinsic (or death receptor) pathway and the intrinsic (or
mitochondrial) pathway [23]. The extrinsic pathway is asso-
ciated with Fas death receptor-mediated caspase-8 activa-
tion and then initiates the activity of downstream caspase-3
[23-25]. Apoptosome formation leads to the activation of
executioner caspase-3, −6 and −7 [26]. The release of cyto-
chrome C, which occurred at the same time as the process-
ing of caspase-3, −8 and −9, has been regarded as a
preceding event for the activation of caspase cascades [27].
The lipophilic cationic probe JC-1 was used to esti-
mate the release of cytochrome C and demonstrate the
disruption of mitochondrial membrane potential (MMP).
ROS are byproducts of normal cellular oxidative processes
and generated in and around mitochondria. It has been
indicated that they can trigger cytochrome C release, cas-
pase activation and subsequent apoptotic biochemichalFigure 8 The effects of hederagenin on the activities of LDH in LoVo
three independent experiments (n = 3). *P < 0.05, **P < 0.01, vs. control.changes [28]. In this study, DCFH-DA was also used to
determine ROS levels. Our results indicated that the in-
duction of hederagenin on apoptosis in LoVo cells might
be related with the mitochondrial membrane potential
disruption.
Bcl-2 family play an important role in cell apoptosis
[29,30]. Multidomain and BH3-only proapoptotic Bcl-2
proteins are antagonized by antiapoptotic family mem-
bers, including Bcl-2 and Bcl-xL [31,32]. It was observed
that Bcl-2 or Bcl-xL promote cell survival by preserving
the integrity of the external mitochondrial membrane
and prevented the release of cytochromec from mito-
chondria [33]. Survivin exists in a novel mitochondrial
pool in turmor cells [34]. In response to cell death
stimulation, mitochondrial survivn is rapidly discharged
in the cytosol to prevent caspase-3 activation and to in-
hibit apoptosis [35,36]. We examined the level of Bcl-2,
Bcl-xL and Survivin, as well as Bax in LoVo cells after
treatment with different concentrations of hederagenincells. The data are expressed as means ± standard deviation from
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hederagenin induced the up-regulation of Bax and
down-regulation of Bcl-2, Bcl-xL and Survivin.
Caspases, a family of cysteine acid proteases, are known
to act as important mediators of apoptosis and contribute
to the overall apoptotic morphology by the cleavage of
various cellular substrates [37]. Caspases activation re-
sulted from cytochrome c release can stimulate mitochon-
drial permeability transition (MPT) [38]. The intrinsic
pathway of apoptosis is associated with the activation of
caspase-9, which cleaves and activates caspase-3 [39]. In
this study, it has been demonstrated that the treatment of
hederagenin increased the expressions of procaspase-9,
procaspase-3 and proPARP. Furthermore, we also ob-
served that hesderagenin increased caspase-9 and caspase-
3 activation. However, no significant changes on caspase-8
were observed in LoVo colon cancer cells. It suggested
that hederagenin induced apoptosis of LoVo colon cancer
cells via intrinsic pathway rather than extrinsic pathway.
Lactate dehydrogenase (LDH) is a glycolytic enzyme. It
is presented in all tissues of the body within the cytoplasm.
Once the cells are damaged, LDH was then released into
extracellular, the extent of cell damage can be detected by
LDH activity [40]. The higher the LDH activity, the more
serious the cell injured [41]. We observed that LDH activ-
ity was significantly increased by hederagenin, and the
dose of 2 μM could increase LDH activity more obviously
than the group with 1 μM. This indicates that hederagenin
has the effect on injury LoVo colon cancer cells.
In the previous report of Park [42], hederagenin which
was isolated from stem bark of Kalopanax pictus Nakai
(Araliaceae) exhibited protruding cytotoxicity to some
extent on several types of tumor cells and mice bearing
Colon 26 and 3LL Lewis lung carcinoma. Also, some re-
search showed that MB, a hederagenin saponin extracted
from Lonicera macranthoides, exhibited strong anti-
tumor effect and mitochondrion-mediated apoptosis in-
duction involved in it [11]. Our results provide more
comprehensive supplement for the mechhanism of heder-
agenin on colon cancer. More research should be
conducted to reveal the underlying mechanism of hedera-
genin on inducing apoptosis of colon cancer cells.
Conclusions
In conclusion, we demonstrated for the first time that
hederagenin, isolated from the leaves of ivy (Hedera
helix L.), could induce apoptosis of LoVo cells through
the mitochondrial apoptotic pathway. Hederagenin could
induce the up-regulation of Bax and down-regulation of
Bcl-2, Bcl-xL and Survivin, the release of cytochrome c,
followed by procaspase-9, procaspase-3 and proPARP
cleavage. Our finding indicated that hederagenin might
be a promising therapeutic candidate for the prevention
and treatment of human colon cancer.Competing interests
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